Find comprehensive information on Non-Small Cell Lung Carcinoma including clinical documentation requirements, medical coding guidelines, and healthcare resources. This resource covers NSCLC diagnosis, staging, TNM classification, ICD-10 codes (C34.x), histology, treatment options, and best practices for accurate medical record keeping. Learn about relevant medical terminology, pathology reports, and the importance of precise coding for optimal reimbursement and patient care related to Non-Small Cell Lung Cancer.
Also known as
Malignant neoplasm of bronchus/lung
Covers various non-small cell lung cancer locations.
Secondary malignant neoplasm of lung
Specifies lung cancer that has spread from elsewhere.
Malignant neoplasm without specification of site
Used when the primary site of lung cancer is unknown.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the NSCLC malignant?
When to use each related code
| Description |
|---|
| Non-Small Cell Lung Cancer |
| Small Cell Lung Cancer |
| Lung Carcinoid Tumor |
Inaccurate coding of NSCLC histology (e.g., adenocarcinoma, squamous cell carcinoma) impacts staging, treatment, and reimbursement.
Incorrect TNM staging or clinical vs. pathological stage documentation can lead to improper grouping and DRG assignment.
Missing or unclear documentation of laterality (right vs. left lung) affects coding accuracy and data analysis for NSCLC.
Q: What are the most recent and effective targeted therapy options for Non-Small Cell Lung Carcinoma based on specific EGFR, ALK, and ROS1 mutation statuses?
A: Targeted therapy selection for Non-Small Cell Lung Carcinoma (NSCLC) is critically dependent on identifying specific driver mutations like EGFR, ALK, and ROS1. For EGFR-mutant NSCLC, first-line treatment typically includes osimertinib, gefitinib, erlotinib, or afatinib. Second or third-generation TKIs like osimertinib are often reserved for patients who develop T790M resistance mutations. In ALK-positive NSCLC, alectinib, brigatinib, ceritinib, crizotinib, or lorlatinib are frequently utilized. For ROS1-positive NSCLC, crizotinib, entrectinib, or lorlatinib are common options. Treatment decisions should be guided by the specific mutation profile, patient characteristics, and disease stage. Explore how molecular testing can guide personalized NSCLC therapy selection and consider implementing comprehensive genomic profiling to inform treatment strategies. Learn more about the latest NCCN guidelines for NSCLC management.
Q: How do I differentiate between squamous cell carcinoma and adenocarcinoma subtypes of Non-Small Cell Lung Carcinoma in challenging diagnostic cases using immunohistochemistry and other ancillary studies?
A: Distinguishing between squamous cell carcinoma and adenocarcinoma, the two main subtypes of NSCLC, can be challenging. Immunohistochemistry (IHC) plays a crucial role. Adenocarcinoma typically stains positive for TTF-1, Napsin A, and sometimes CK7, while staining negative for p40 and p63. Squamous cell carcinoma usually shows the opposite pattern, staining positive for p40 and p63 and negative for TTF-1 and Napsin A. In difficult cases where IHC is inconclusive, molecular testing can help identify specific driver mutations which may suggest a particular subtype. For example, EGFR mutations are almost exclusively seen in adenocarcinoma. Consider implementing a multidisciplinary approach involving pathologists, oncologists, and pulmonologists to ensure accurate subtyping in complex NSCLC cases. Explore the latest research on the role of molecular testing in challenging NSCLC diagnoses.
Patient presents with concerning symptoms suggestive of non-small cell lung cancer (NSCLC). Chief complaints include persistent cough, hemoptysis, dyspnea, and unintentional weight loss. Patient reports a history of smoking (30 pack-years) and occupational exposure to asbestos. Physical examination reveals decreased breath sounds in the right upper lobe and palpable supraclavicular lymphadenopathy. Imaging studies, including chest X-ray and CT scan of the chest, demonstrate a suspicious mass in the right upper lobe with potential mediastinal involvement. A PET scan was ordered to evaluate for metastatic disease. Pulmonary function tests (PFTs) show mildly reduced FEV1 and FVC, consistent with obstructive lung disease. Bronchoscopy with biopsy was performed, and pathology confirms the diagnosis of non-small cell lung cancer, adenocarcinoma subtype. Staging workup is underway to determine the extent of the disease (TNM staging). Differential diagnoses included pneumonia, bronchitis, and other lung malignancies, but these were ruled out based on imaging and biopsy results. The patient was referred to medical oncology and thoracic surgery for further evaluation and discussion of treatment options, which may include surgery, chemotherapy, radiation therapy, targeted therapy, or immunotherapy. Genetic testing (EGFR, ALK, ROS1) was ordered to guide personalized treatment decisions. Patient education provided regarding lung cancer diagnosis, treatment, and prognosis. Follow-up appointment scheduled to review staging results and finalize treatment plan. ICD-10 code C34.90 (Malignant neoplasm of unspecified part of bronchus or lung) is documented. CPT codes for the procedures performed, such as bronchoscopy and biopsy (31628), chest CT (71250), and PET scan (78815), are documented separately. This documentation supports medical necessity for the diagnostic workup and ongoing treatment of NSCLC.